Epratuzumab for the treatment of systemic lupus erythematosus

Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome

(2018) Jacques-Eric Gottenberg et al.   Arthritis & Rheumatology

Biotherapies in systemic lupus erythematosus: New targets

(2017) Estibaliz Lazaro et al.   JOINT BONE SPINE

The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies

(2017) Frances Rees et al.   RHEUMATOLOGY

The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults

(2017) Caroline Gordon et al.   RHEUMATOLOGY

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials

(2017) Megan E. B. Clowse et al.   Arthritis & Rheumatology

The paradoxical roles of C1q and C3 in autoimmunity

(2016) Diane Scott et al.   IMMUNOBIOLOGY

The BAFFling effects of rituximab in lupus: danger ahead?

(2016) Michael R. Ehrenstein et al.   Nature Reviews Rheumatology

Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study

(2016) D. J. Wallace et al.   ARTHRITIS CARE & RESEARCH

The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus

(2015) Thomas Dörner et al.   AUTOIMMUNITY REVIEWS

Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus: Results from a phase 1/2 randomized study

(2015) Tomomi Tsuru et al.   Modern Rheumatology

Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients

(2015) Vanessa Fleischer et al.   ARTHRITIS RESEARCH & THERAPY

B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use

(2015) Md Yuzaiful Md Yusof et al.   Current Rheumatology Reports

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)

(2014) David Isenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

The incidence and prevalence of systemic lupus erythematosus in the UK, 1999–2012

(2014) Frances Rees et al.   ANNALS OF THE RHEUMATIC DISEASES

Advances in the assessment of lupus disease activity and damage

(2014) Vijay Rao et al.   CURRENT OPINION IN RHEUMATOLOGY

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

(2013) Daniel J Wallace et al.   ANNALS OF THE RHEUMATIC DISEASES

Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab

(2013) E. A. Rossi et al.   BLOOD

Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up

(2013) Daniel J. Wallace et al.   RHEUMATOLOGY

Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006

(2013) V. Strand et al.   RHEUMATOLOGY

Population-Based Incidence and Prevalence of Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology and Surveillance Program

(2013) Emily C. Somers et al.   Arthritis & Rheumatology

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus

(2012) Michelle Petri et al.   ARTHRITIS AND RHEUMATISM

CD22 ligation inhibits downstream B cell receptor signaling and Ca2+flux upon activation

(2012) N. Sieger et al.   ARTHRITIS AND RHEUMATISM

CD22 and Autoimmune Disease

(2012) Thomas Dörner et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

(2011) Richard Furie et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

Numerical scoring for the BILAG-2004 index

(2010) Chee-Seng Yee et al.   RHEUMATOLOGY

Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus

(2010) Capucine Daridon et al.   ARTHRITIS RESEARCH & THERAPY

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

(2009) Joan T. Merrill et al.   ARTHRITIS AND RHEUMATISM

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

(2009) K. R. Carson et al.   BLOOD

PI3 Kinase Signals BCR-Dependent Mature B Cell Survival

(2009) Lakshmi Srinivasan et al.   CELL

Numerical scoring for the Classic BILAG index

(2009) L. Cresswell et al.   RHEUMATOLOGY

The BILAG-2004 index is sensitive to change for assessment of SLE disease activity

(2009) Chee-Seng Yee et al.   RHEUMATOLOGY

The role of mannose-binding lectin in systemic lupus erythematosus

(2008) Odirlei André Monticielo et al.   CLINICAL RHEUMATOLOGY

Systemic Lupus Erythematosus

(2008) Anisur Rahman et al.   NEW ENGLAND JOURNAL OF MEDICINE